Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Revolutionary Approach to Left Atrial Appendage (LAA) Elimination (StrokeAvoidance)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Israel
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 36.0
Total project cost (EUR): 2499999.0
EU funding (EUR): 2499999.0
Participants: 1
Project status: SIGNED

Stroke is the second leading cause of death and disability in Europe, resulting in 1 million deaths annually and posing a significant financial burden on national health systems. The main risk factor for stroke is atrial fibrillation (AF), the most common type of cardiac arrhythmia that causes blood clots to develop in the left atrial appendage, which increases the stroke risk by five times. Append Medical is revolutionizing the rules of the game for reducing stroke risk in AF patients through a one-time intervention that eliminates the need for a permanent metal implant in the heart, leaving only a suture lasso. This innovation dramatically reduces the procedure-related risks, such as incomplete sealing, device-related thromboembolism, and device migration, leading to enhanced patient safety. Notably, this improvement results in significant cost savings for medical centers, reducing healthcare service requirements and hospital stays due to procedure-related complications. For the first time ever, our Appligator system enables a complete endocardial closure of the left atrial appendage (LAA) using an implant-free, secure, and straightforward tissue manipulation technique. Simplicity is central to our system's design, utilizing a standard transfemoral/transcatheter approach, which broadens the range of cardiologists who can perform the procedure. This approach promotes widespread use of LAA closure, removes barriers to access, and ultimately improves patient outcomes, making this lifesaving treatment more accessible to a broader population. Under the proposed EIC project, we will progress towards the EU market approval for our innovative LAA device in line with the Medical Devices Regulation (MDR) class III devices requirements. With the EIC support, by 2029, our solution could be the world’s first approved transcatheter endocardial no-implant LAA elimination system (first mover advantage).

Keywords: interventional cardiology,cardiovascular,atrial fibrillation,stroke risk reduction,left atrial appendage laa
A game-changer and FDA’s breakthrough device designated for the safe delivery of treatments through the heart´s surface via a minimally invasive approach. (ViaOne)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Israel
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2080600.0
EU funding (EUR): 2080600.0
Participants: 1
Project status: SIGNED

According to the WHO, 17.9 million people die from cardiovascular diseases each year, including arrhythmias, heart failure and stroke. Indeed, Ventricular tachycardia (VT), one type of arrhythmia and primary cause of sudden cardiac death (SCD), accounts for 600,000 deaths in the EU annually. Although in recent years, cardiologists have recognized the benefits for the patient of DIRECT ACCESS TO THE HEART'S SURFACE for highly valuable treatments, this is performed as a last resort only, since the current gold standard consists of using a long hand-held needle, which carries 30% risk of PUNCTURING THE HEART. ViaOne is an innovative breakthrough platform that enables safe and minimally invasive access to the outer surface of the heart to deliver a wide variety of advanced cardiac treatments, ranging from structural heart disease to arrhythmias and heart failure conditions. Our innovation avoids puncturing the heart muscle, improving patients´s recovery while diminishing healthcare costs. CardioVia has successfully validated the technology with pre-clinical and FIH clinical trials with highly positive feedback; Our studies were published on JACC clinical EP and Journal of Interventional Cardiac Electrophysiology, tier 1 peer-reviewed medical journals. Furthermore, given the encouraging results, CardioVia’s studies have not only been showcased at multiple global professional conferences but have also been highlighted as a Late Breaking Clinical Trial awardee by the American Heart Rhythm Society, underscoring its significant contribution to advancing cardiac health. The EIC grant will enable the optimisation and clinical validation of our breakthrough device to get the commercialisation clearance (TRL 8) required to start sales. CardioVia plans to launch in the EU (DE – Europe’s largest cardiology market; PL & IL – clinical validation sites) by 2026 and reach the break-even point by 2027.

Keywords: electrophysiology,ablation,heart s surface access,cardiac intervention,arrhythmias,ventricular tachycardia,atrial fibrillation,cardiovascular,
TRANSFORMATIVE NON-INVASIVE CAUSAL MECHANOSTICS PLATFORM TO EFFECTIVELY TRIAGE AND TREAT ENDOMETRIOSIS (TRANSCEND)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: United Kingdom,Poland,Denmark
Call: EIC Accelerator Open 2024 (HORIZON-EIC-2024-ACCELERATOR-02, 2024)
Start date: 2025-06-01
End date: 2027-05-31
Duration (months): 24.0
Total project cost (EUR): 3563272.86
EU funding (EUR): 2494291.0
Participants: 3
Project status: SIGNED

Complex chronic diseases like endometriosis consume 80% of Europe’s healthcare budget. Endometriosis is a painful condition in which the lining of the uterus grows outside the uterus. It affects 200 million women worldwide at the peak of their productive and reproductive years and costs Europe €70bn/year. As with other complex chronic diseases, endometriosis results from multiple combinations of genetic, clinical and environmental factors, making it difficult to diagnose and treat. On average it takes 8 years to diagnose, typically involving 10+ medical consultations. The current diagnostic standard is laparoscopy - an invasive, expensive and painful surgery. Neither non-invasive, accurate early-diagnostic tools nor effective treatments currently exist for endometriosis. As many as 60% of endometriosis cases are undiagnosed. As such, a pressing medical need exists for an affordable and scalable precision diagnostic solution to guide personalised treatments. Building on successful results from our Horizon 2020 FEMaLe project, this EIC Accelerator project will clinically validate the world’s first accurate, cost-effective, scalable and simple to use diagnostic test to predict an individual's risk of developing endometriosis based on the underlying causal mechanisms of the disease. Using these novel insights, this project will demonstrate how the diagnostic can be used to target clinically repurposed drugs to successfully treat specific disease subtypes. Having identified critical disease signatures and potential drug candidates to repurpose (TRL6 achieved), EIC support is essential to certify our novel diagnostic as a Class C IVDR device and prove the efficacy of repurposed drugs to treat endometriosis for a €4bn global market. Overcoming these remaining risky and challenging barriers will enable us to achieve €251m in revenues, €171m in net profits and grow our highly skilled team to 73 FTEs by Y5 post-project, thereby realising our full commercial potential.

Keywords: combinatorial analytics,clinical decision support,predicate devices,triage,triagnostics,mechanostics,complex chronic diseases,ivdr,laboratory developed test,lossless dimensionality reduction
Evolution of Mechanisms for Sex Chromosome Dosage Compensation and Gene Regulation (EMERGE)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Countries involved: Switzerland
Call: ERC CONSOLIDATOR GRANTS (ERC-2025-COG, 2025)
Start date: 2026-08-01
End date: 2031-07-31
Duration (months): 60.0
Total project cost (EUR): 1999177.0
EU funding (EUR): 1999177.0
Participants: 1
Project status: SIGNED

There is a remarkable diversity of phenotypes among multicellular animals, including differences between males and females. A major driver of phenotypic variation stems from differences in gene regulation. The evolution of these regulatory mechanisms is a central, yet unresolved question in biology. Sex chromosome dosage compensation (SCDC) is an epigenetic process that equalizes sex chromosomal gene expression between males and females. EMERGE uses SCDC as a model to uncover how and why epigenetic mechanisms evolve and function across animals. We will employ a taxonomic gradient from (1) molecular studies in malaria mosquitos to (2) comparative mechanistic analyses across multiple insects, and finally to (3) a broad investigation across all animal clades. First, we will determine how a novel SCDC pathway in malaria mosquitos evolved to specifically regulate the X chromosome. To achieve this, we will use heterologous expressions, alongside in vitro biochemistry and proximity proteomics. Second, we will assess the physiological relevance of SCDC to determine why its absence is lethal in only certain contexts and species. We will test how proteome homeostasis, transcriptional noise, and critical genes influence essentiality. Third, we will explore the diversity of SCDC mechanisms across dozens of animal species with heteromorphic sex chromosomes, including unexplored phyla such as Cnidaria or Mollusca. Employing microscopy, transcriptomics, proteomics, and epigenome profiling, we will study SCDC patterns, conserved and lineage-specific adaptations, as well as regulatory mechanisms. Our findings are expected to reveal general principles of how chromatin controls gene expression, responds to dosage imbalances, and evolves across the animal tree of life. By comprehensively investigating both sexes, EMERGE will at the same time shed light on the regulatory and physiological differences between males and females, a heavily overlooked aspect in research and healthcare.

Keywords: sex chromosome evolution,chromosome wide regulation,dosage compensation,gene dosage
A novel and accurate emotion recognition system for real-time and continuous patient monitoring in psychiatry (ADAPTE)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: France
Call: EIC Accelerator Open 2023 (HORIZON-EIC-2023-ACCELERATOR-01, 2023)
Start date: 2023-11-01
End date: 2026-04-30
Duration (months): 30.0
Total project cost (EUR): 3568155.0
EU funding (EUR): 2497708.0
Participants: 1
Project status: SIGNED

150M people suffer from mental disorders in Europe & this number is sharply increasing. There are not enough psychiatrists to cope with the situation: a psychiatrist sees 1,000 patients in sessions separated every 3-4 months. Psychiatrists have no way to know if a patient's treatment is working and if there is any risk of relapse/suicide between sessions. A patient's emotional status gives insights into treatment effectiveness and diagnosis of major depressive disorder, but there are no accurate tools to monitor emotions remotely and continuously. Cephalgo has solved this challenge & developed the first accurate, remote & continuous emotion tracker to monitor treatment effectiveness, and predict the best course of treatment for a given patient profile. Combining speech analysis & an AI-driven emotion recognition algorithm, our AI detects emotions with high accuracy & predicts the best treatment to reduce the trial & error approach currently employed in psychiatry.

Keywords: emotion tracking,eco friendly hydrogel,diagnosis,convolutional neural network,mood disorders,digital health therapeutics,wearable,eeg,dry electrodes,emotion recognition,continuous patient monitoring
RunML: Tailored computing solutions with hardware accelerated system for Artificial Intelligence and Machine Learning (RunML)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Sweden
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2470000.0
EU funding (EUR): 2470000.0
Participants: 1
Project status: SIGNED

Machine Learning (ML) and Artificial Intelligence (AI) are becoming omnipresent with their use in almost all fields. The AI market is estimated to be valued at €2.446,4B by 2032. However, today’s computing systems are still not optimized for AI applications. AI/ML computations are not streamlined, the algorithms are overly complex and not optimized for precision. Therefore, AI applications are expensive to run, and have a High energy footprint. By 2027, AI servers will need 0,5% of the world's electricity. At INCEPTRON, we have built RunML, a breakthrough system to provide hardware acceleration for AI/ML applications. Our transparent, scalable solution is a pioneer on the market that provides a tailor-made combination of programmability, flexibility, and performance for each customer. Our platform uses Field-Programmable Gate Arrays (FPGAs) available in public clouds, and automatically programs them tailored to the users’ needs to provide up to 100x Faster Inference Performance, 50% Lower Cloud Cost and 66% Less Energy Consumption than current industry standard. With RunML, Inceptron is poised to be a market leader in delivering customized AI solutions with strong IP portfolio (2 pending patent applications, 3-4 in process). We need EIC Accelerator funding to facilitate technology maturation and validation for RunML. This funding will allow us to automate manual processes in our workflow accelerating scale-up. We will also validate our system with pilot partners (Axis) and expand our team from 12 to 48 FTEs, before entering the market in Q2 2027. Financial forecasts project break-even for 2027 with a yearly revenue of € 98,8 M by 2030. The failure to secure this funding would result in a 1,5-2-year delay in the implementation of our go-to-market plan and will cost INCEPTRON its first mover advantage. Therefore, we request a €2.47M EIC Grant and €1.2M Equity to bring our first of its kind, environment friendly, affordable tailored AI solution to the market.

Keywords: machine learning,artificial intelligence,hardware acceleration,cloud computing,field programmable gate arrays,algorithms,optimization
SHIFT - Scalable High-throughput Innovations for Faster Toxicity Testing (SHIFT)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Germany
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 835093.0
EU funding (EUR): 835093.0
Participants: 1
Project status: SIGNED

Around 350,000 different chemicals and mixtures are used worldwide, yet for most of these, possible harmful effects on brain development are poorly understood. The high costs and time requirements of rodent in vivo studies make routine testing of substances for developmental neurotoxicity (DNT) impractical. This large knowledge gap has social and economic implications and can leave citizens concerned for their children’s health. DNTOX provides human cell-based DNT tests as a service to the chemical and pharmaceutical industry. In comparison to animal studies, those tests are more cost-effective, faster, more relevant for human health, and have received support from regulatory authorities and the Organization for Economic Co-operation and Development (OECD). However, one of these tests sets a limit on both the maximum testing capacity and the lowest possible price that DNTOX can offer to clients. DNTOX proposes to develop the test further which will halve the price and increase the testing capacity by a factor of 4. Combined with a future company scale-up by a factor of 2, this will allow DNTOX to cover one third of the substances that are (re-)authorized each year for use in the European Union. The proposed developments align with the EU Chemicals Strategy for Sustainability, which is part of the European Green Deal, as well as UN Sustainable Development Goals 3, 6, and 8. The intended price reduction will make the DNTOX services more attractive for customers to implement DNT screening already during substance development, thus supporting the production of chemicals that are safe and sustainable by design. The considerable risk associated with this project makes it difficult to acquire capital to cover the estimated budget of € 1.2 million. Nonetheless, with years of experience in test development and DNT testing, DNTOX’ experts are confident that they can develop a new solution with the ability to disrupt the landscape of substance safety testing.

Keywords: developmental neurotoxicity,alternatives to animal testing,safer chemicals by design,in vitro,human relevance
CirculArity Enhancements by Low quality Scrap Analysis and Refinement (CAESAR)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Digital, Industry and Space
Theme: Industry
Destination: Climate neutral, Circular and Digitised Production
Action type: Innovation actions
Partnership: Clean Steel (co-programmed)
Countries involved: Belgium,Spain,France,Germany,Luxembourg
Call: Improvement of the yield of the iron and steel making (Clean Steel Partnership) (IA) (HORIZON-CL4-2021-TWIN-TRANSITION-01, 2021)
Start date: 2022-06-01
End date: 2026-05-31
Duration (months): 48.0
Total project cost (EUR): 7959397.9
EU funding (EUR): 5556227.0
Participants: 13
Project status: SIGNED

Today, the European Union?s steel sector is a modern industry with its main customer base found within the EU home markets, particularly in high-end segments. However, challenges remain to keep the EU steel sector both competitive at a global level and climate-neutral, in line with the European Green Deal and the CleanSteel Partnership?s vision. The scrap usage in steelmaking is a common practice to improve the process? sustainability, as it decreases the use of virgin raw materials and boosts the circularity of the sector (decreasing CO2 emissions and electivity consumption). Nevertheless, the current trend in the EU scrap market points at a slight decrease in the pre-consumer scrap and an increase in the short- and long-term of the post-consumer scrap stream, due to an increase in steel consumption. Nowadays, these ?low-quality? scrap streams are not suitable for most applications, thus limiting their use in steelmaking. In order to increase the steel scrap recycling capacity and energy efficiency, while keeping EU competitive and safe in terms of raw materials imports, energy consumption and climate change impact, innovative technologies to ?clean? the scrap before it reaches the steel furnaces need to be implemented. CAESAR gathers up steelmakers, technology developers and research centers in a joint effort to validate, at full-size industrial scale, integrated scrap upgrading, sorting and characterization technologies, thus enabling to untap volumes of low-quality scrap streams in Europe, while keeping a high-quality product and generating valorization routes for all the non-ferrous fractions obtained, towards a zero waste steel sector.

Keywords: steel scrap utilisation,circular economy
Information control processes: an alternative, cross-language and multidimensional approach to study their development (CTRL-ALT-DEV)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Italy,United States
Call: MSCA Postdoctoral Fellowships 2023 (HORIZON-MSCA-2023-PF-01, 2023)
Start date: 2025-09-01
End date: 2028-08-31
Duration (months): 36.0
Total project cost (EUR): 288859.2
EU funding (EUR): 288859.2
Participants: 2
Project status: SIGNED

Vast research efforts have been made to understand how executive control (i.e., the domain-general processes needed to flexibly plan and monitor goal-oriented behavior) evolves in children to help them focus on a task (e.g., studying) while resisting interferences (e.g., phone notifications), ensuring an optimal cognitive development and future success in life. Still, no study has examined age-related changes in (domain-specific) semantic control, namely the processes needed to focus on non-dominant aspects of knowledge based on the current goal and context demands, rather than automatically retrieving the dominant ones (e.g., during symbolic play, the non-dominant shape of a banana is used to make it a phone, ignoring its dominant edibility). Semantic control is intrinsically related to the development of memory for concepts meaning and, in turn, the typology of a given language, but these aspects are unexplored. Moreover, its development is naturally paralleled by cortical maturation, but their interplay remains a hot topic of debate. This project aims to address these issues by studying for the first time the development of executive and semantic control and their relation at three levels: behavior, models, and brain. I will build a battery of control tasks using a gamification method for online assessment of English and Italian children at different ages. High-density electroencephalography will also be recorded to assess their task-related brain activity and organization. I will use state-of-the-art analytical approaches to assess the development of control processes (O1), their relation (O2), and language-dependence (O3) and functional brain bases (O4). Results will provide a new brain-behavior theoretical model of cognitive control acquisition embedding semantic control, opening new research agendas in cognitive neurosciences and education and paving the way to build trainings in control functions for children with typical and atypical development.

Keywords: cognitive development,gamification,semantic memory,semantic control,executive functions,controlled semantic cognition,eeg,neural underpinnings,structural equation modeling,ersp,language